脐带间充质干细胞治疗终末期肝硬化的临床观察
|
摘要
肝硬化(hepatic cirrhosis)是由多种原因引起的肝脏损害,表现为肝细胞变性坏死,纤维组织增生,肝细胞结节状再生,肝小叶结构变形,血液循环途径被改建,最终导致肝硬化。根据病因分类,肝硬化主要有病毒性肝硬化、酒精性肝硬化、胆汁性肝硬化、自身免疫性肝硬化及隐原性肝硬化等。我国以病毒性肝硬化为主,其中主要为乙型肝炎病毒感染造成,很多病人无法长期规范化治疗最终致肝硬化。肝硬化病人有门脉高压和肝功能障碍,病人常因消化道大出血和肝性脑病死亡。因此,肝硬化治疗是一项长期艰巨的任务,有效的方法为肝移植,因肝脏供体少,临床工作难以大量展开,越来越多的研究者致力于研究能替代肝移植的方法,间充质干细胞成为新的方向。
间充质干细胞(Mesenchymal stem cells,MSCs)属于干细胞家族,主要存在于骨髓、脐带、脐血和胚胎中。因具有多向分化潜能、造血支持、免疫调控和自我复制等特点,受到人们的关注。间充质干细胞在体内或体外诱导条件下可以分化为骨、软骨、脂肪、肌肉、肌腱、神经、类肝细胞、心肌等组织细胞,连续传代后仍具有多向分化潜能,可作为理想种子细胞用于炎症病变及衰老引起的器官修复。骨髓间充质干细胞应用于临床较早,但抽取骨髓为有创性检查,增加了病人痛苦,越来越多的学者致力于研究脐带来源的间充质干细胞。脐带间充质干细胞来源广泛,收集脐带为无创操作,且治疗肝硬化有促进肝脏再生、提高患者生活质量的作用,在临床上应用越来越受到重视。
目的:制备足月顺产胎儿脐带来源的间充质干细胞,探讨体外分离、培养、鉴定
方法,观察脐带间充质干细胞治疗终末期肝硬化的临床疗效。方法:无菌条件下采集新生儿脐带,经过分离,培养获得间充质干细胞,流式细胞仪表面抗原测定(CD29、CD105、CD34、CD45);选择50例肝硬化患者,26例患者在内科治疗基础上经前臂静脉或肝动脉插管进行MSCs移植,术后定期检测肝功能、凝血功能及临床症状,并观察同期的症状体征和不良反应,同时随机选择24例仅以内科治疗的肝硬化患者做为对照组,两组间进行比较。
结果:
(1)培养的脐带间充质干细胞呈长梭形、旋涡状生长。P1代消化后传代,贴壁时间约48h左右,2-3W长满80%。P6代以内的细胞增殖无明显差异。P3-P6代生长速度较快,24h贴壁,48h长满70%,72h长满80%,P3-P6代内无明显分化。
(2)细胞免疫表型显示表达间充质干细胞的特异性标记CD29;但不表达造血干细胞表面标记CD34、CD45。这与骨髓间充质干细胞的表型一致。
(3)脐带间充质干细胞移植后,治疗组ALB、PA和Fbg水平比对照组明显升高(P﹤0.05),PT时间与对照组相比明显降低(P﹤0.05)。
(4)治疗组患者从治疗后1周开始,乏力、腹胀、纳差明显好转,12周后患者腹水明显减少。26例移植患者术中未出现严重不良反应,无与移植相关的严重并发症。
结论:
(1)本实验用双酶消化法分离出间充质干细胞,经过冻存、复苏后细胞损伤小,多次传代后细胞分化少,增殖能力稳定。
(2)人脐带间充质干细胞经过流式细胞仪测定后,表达间充质干细胞的表型,不表达造血干细胞表型,与骨髓来源的间充质干细胞检测一致。
(3)人脐带间充质干细胞治疗终末期肝硬化,可提高患者ALB、PA、Fbg,缩短PT,改善了患者的临床症状。
(4)人脐带间充质干细胞移植肝硬化患者,具有良好的安全性。
Hepatic cirrhosis are caused by a variety of liver damage, liver cells showing degeneration and necrosis, fibrosis, nodular regeneration, lobular architecture distortion, blood circulation route to be converted, eventually leading to cirrhosis. Based on etiology, hepatic cirrhosis are classified to viral cirrhosis, alcoholic cirrhosis, parasitic liver cirrhosis, toxic cirrhosis, biliary cirrhosis, autoimmune cirrhosis, congestive cirrhosis, cryptogenic cirrhosis and so on. Hepatic cirrhosis caused by Hepatitis B virus is very common in China. According to statistics, about 9,300 million people carry hepatitis B virus, of which about 30 million are hepatitis B patients. Due to lack of effective treatment for hepatitis B virus and high cost of treatment, many patients can not receive long-term treatment ultimately, and eventually lead to cirrhosis. Patients of hepatic cirrhosis often suffer from portal hypertension and liver dysfunction, and finally result in death due to hepatic encephalopathy and gastrointestinal bleeding. Therefore, the treatment of hepatic cirrhosis is a difficult task. Effective therapy for hepatic cirrhosis is liver transplantation. But it is hard to be carried out in clinical work for lack of liver donor. More and more scientists focus on some other methods replacing liver transplantation. Mesenchymal stem cells is one of the options for treatment of hepatic cirrohsis.
Mesenchymal stem cell is a member of stem cells. Mesenchymal stem cells are mainly in the bone marrow, umbilical cord, cord blood, embryos. Mesenchymal stem cells received much attention because of multiple differentiation potential, hematopoietic support, immune regulation, self-replication and other characteristics. Mesenchymal stem cells can serve as ideal seed cells for inflammation caused by disease and organ repair due to aging. In vivo or in vitro conditions, MSCs can be induced and differentiated into bone, cartilage, fat, muscle, tendon, nerve, liver cells, heart and so on. MSCs’continuous passage has multiple differentiation potential. Mesenchymal stem cells are very early to be used clinically. Bone marrow extraction is invasive and increase patients,suffering. A growing number of scholars have been working on the umbilical cord derived mesenchymal stem cells. Umbilical cords are easy to be collected non-invasively, and therefore umbilical mesenchymal stem cells are commonly used in treatment of a variety of diseases in clinical practice, including liver cirrhosis.
Objective: Cultivate mesenchyma stem cells the full-term childbirth embryo umbilical cord,explore the method of umbilical cord mesenchymal stem cells separation in vitro, proliferation, identification, and observe the efficacy in treating of end-stage hepatic cirrhosis.
Methods: Collect newborn umbilical cord under sterile conditions, culture mesenchymal stem cells after separation, take cells for flow cytometry checking CD29, CD105, CD34, CD45. Select 50 cases of liver cirrhosis, 26 patients received basic medication and MSCs transplantation as well by way of forearm vein or the hepatic artery. Liver function, blood coagulation function, clinical symptoms, signs, symptoms and adverse reactions were monitored postoperatively. In addition, 24 patients with cirrhosis are randomly selected to receive regular medical treatment as control.
Results:
(1) Mesenchymal stem cells from umbilical cord are spiral-shaped growth in culture. Cells of passage 1 were digested and passaged. Its adherence time is about 48h. It covered about 80% after 2-3w. Passage 3 - passage 6 cells grow faster, adhere in 24h covering 70% in 48h, covering 80% in 72h. There is no significant difference in proliferation and differentiation within the passage 6.
(2) The phenotype of cells were CD29, which is mesenchymal stem cells' specific marker, but did not express hematopoietic stem cell surface markers CD34, CD45. The cultured mesenchymal stem cells cells and bone marrow mesenchymal stem cells are in the same of phenotypic expression.
(3) After UCMSCs treatment, the level of albumin, prealbumin and fibrinogen were significantly increased in treatment group than in control group (P<0.05), and the levels of prothrombin time was obviously reduced (P<0.05).
(4) One week after treatment, the symptoms such as fatigue, abdominal distension, anorexia have been improved in treatment group. 12 weeks later, the amounts of ascites were significantly reduced. No serious adverse reactions and complications occurred in 26 cases of transplant patients after treatment.
Conclusion:
(1) Mesenchymal stem cells from isolated umbilical cord are less damaged after cryopreservation and recovery. After several passages, cells had less differentiation, more stable proliferation.
(2) Human umbilical cord mesenchymal stem cells were detected by flow cytometry, the expression of mesenchymal stem cell phenotype, did not express hematopoietic stem cell phenotype. Cultured Cells and bone marrow mesenchymal stem cells were in the same of phenotypic expression.
(3) Treatment of hepatic cirrhosis by human umbilical cord mesenchymal stem cells can increase patient’s ALB, PA, Fbg, shorten the PT and improve clinical symptoms.
(4) Human umbilical cord mesenchymal stem cell transplantation in patients with hepatic cirrhosis is safe.
间充质干细胞(Mesenchymal stem cells,MSCs)属于干细胞家族,主要存在于骨髓、脐带、脐血和胚胎中。因具有多向分化潜能、造血支持、免疫调控和自我复制等特点,受到人们的关注。间充质干细胞在体内或体外诱导条件下可以分化为骨、软骨、脂肪、肌肉、肌腱、神经、类肝细胞、心肌等组织细胞,连续传代后仍具有多向分化潜能,可作为理想种子细胞用于炎症病变及衰老引起的器官修复。骨髓间充质干细胞应用于临床较早,但抽取骨髓为有创性检查,增加了病人痛苦,越来越多的学者致力于研究脐带来源的间充质干细胞。脐带间充质干细胞来源广泛,收集脐带为无创操作,且治疗肝硬化有促进肝脏再生、提高患者生活质量的作用,在临床上应用越来越受到重视。
目的:制备足月顺产胎儿脐带来源的间充质干细胞,探讨体外分离、培养、鉴定
方法,观察脐带间充质干细胞治疗终末期肝硬化的临床疗效。方法:无菌条件下采集新生儿脐带,经过分离,培养获得间充质干细胞,流式细胞仪表面抗原测定(CD29、CD105、CD34、CD45);选择50例肝硬化患者,26例患者在内科治疗基础上经前臂静脉或肝动脉插管进行MSCs移植,术后定期检测肝功能、凝血功能及临床症状,并观察同期的症状体征和不良反应,同时随机选择24例仅以内科治疗的肝硬化患者做为对照组,两组间进行比较。
结果:
(1)培养的脐带间充质干细胞呈长梭形、旋涡状生长。P1代消化后传代,贴壁时间约48h左右,2-3W长满80%。P6代以内的细胞增殖无明显差异。P3-P6代生长速度较快,24h贴壁,48h长满70%,72h长满80%,P3-P6代内无明显分化。
(2)细胞免疫表型显示表达间充质干细胞的特异性标记CD29;但不表达造血干细胞表面标记CD34、CD45。这与骨髓间充质干细胞的表型一致。
(3)脐带间充质干细胞移植后,治疗组ALB、PA和Fbg水平比对照组明显升高(P﹤0.05),PT时间与对照组相比明显降低(P﹤0.05)。
(4)治疗组患者从治疗后1周开始,乏力、腹胀、纳差明显好转,12周后患者腹水明显减少。26例移植患者术中未出现严重不良反应,无与移植相关的严重并发症。
结论:
(1)本实验用双酶消化法分离出间充质干细胞,经过冻存、复苏后细胞损伤小,多次传代后细胞分化少,增殖能力稳定。
(2)人脐带间充质干细胞经过流式细胞仪测定后,表达间充质干细胞的表型,不表达造血干细胞表型,与骨髓来源的间充质干细胞检测一致。
(3)人脐带间充质干细胞治疗终末期肝硬化,可提高患者ALB、PA、Fbg,缩短PT,改善了患者的临床症状。
(4)人脐带间充质干细胞移植肝硬化患者,具有良好的安全性。
Hepatic cirrhosis are caused by a variety of liver damage, liver cells showing degeneration and necrosis, fibrosis, nodular regeneration, lobular architecture distortion, blood circulation route to be converted, eventually leading to cirrhosis. Based on etiology, hepatic cirrhosis are classified to viral cirrhosis, alcoholic cirrhosis, parasitic liver cirrhosis, toxic cirrhosis, biliary cirrhosis, autoimmune cirrhosis, congestive cirrhosis, cryptogenic cirrhosis and so on. Hepatic cirrhosis caused by Hepatitis B virus is very common in China. According to statistics, about 9,300 million people carry hepatitis B virus, of which about 30 million are hepatitis B patients. Due to lack of effective treatment for hepatitis B virus and high cost of treatment, many patients can not receive long-term treatment ultimately, and eventually lead to cirrhosis. Patients of hepatic cirrhosis often suffer from portal hypertension and liver dysfunction, and finally result in death due to hepatic encephalopathy and gastrointestinal bleeding. Therefore, the treatment of hepatic cirrhosis is a difficult task. Effective therapy for hepatic cirrhosis is liver transplantation. But it is hard to be carried out in clinical work for lack of liver donor. More and more scientists focus on some other methods replacing liver transplantation. Mesenchymal stem cells is one of the options for treatment of hepatic cirrohsis.
Mesenchymal stem cell is a member of stem cells. Mesenchymal stem cells are mainly in the bone marrow, umbilical cord, cord blood, embryos. Mesenchymal stem cells received much attention because of multiple differentiation potential, hematopoietic support, immune regulation, self-replication and other characteristics. Mesenchymal stem cells can serve as ideal seed cells for inflammation caused by disease and organ repair due to aging. In vivo or in vitro conditions, MSCs can be induced and differentiated into bone, cartilage, fat, muscle, tendon, nerve, liver cells, heart and so on. MSCs’continuous passage has multiple differentiation potential. Mesenchymal stem cells are very early to be used clinically. Bone marrow extraction is invasive and increase patients,suffering. A growing number of scholars have been working on the umbilical cord derived mesenchymal stem cells. Umbilical cords are easy to be collected non-invasively, and therefore umbilical mesenchymal stem cells are commonly used in treatment of a variety of diseases in clinical practice, including liver cirrhosis.
Objective: Cultivate mesenchyma stem cells the full-term childbirth embryo umbilical cord,explore the method of umbilical cord mesenchymal stem cells separation in vitro, proliferation, identification, and observe the efficacy in treating of end-stage hepatic cirrhosis.
Methods: Collect newborn umbilical cord under sterile conditions, culture mesenchymal stem cells after separation, take cells for flow cytometry checking CD29, CD105, CD34, CD45. Select 50 cases of liver cirrhosis, 26 patients received basic medication and MSCs transplantation as well by way of forearm vein or the hepatic artery. Liver function, blood coagulation function, clinical symptoms, signs, symptoms and adverse reactions were monitored postoperatively. In addition, 24 patients with cirrhosis are randomly selected to receive regular medical treatment as control.
Results:
(1) Mesenchymal stem cells from umbilical cord are spiral-shaped growth in culture. Cells of passage 1 were digested and passaged. Its adherence time is about 48h. It covered about 80% after 2-3w. Passage 3 - passage 6 cells grow faster, adhere in 24h covering 70% in 48h, covering 80% in 72h. There is no significant difference in proliferation and differentiation within the passage 6.
(2) The phenotype of cells were CD29, which is mesenchymal stem cells' specific marker, but did not express hematopoietic stem cell surface markers CD34, CD45. The cultured mesenchymal stem cells cells and bone marrow mesenchymal stem cells are in the same of phenotypic expression.
(3) After UCMSCs treatment, the level of albumin, prealbumin and fibrinogen were significantly increased in treatment group than in control group (P<0.05), and the levels of prothrombin time was obviously reduced (P<0.05).
(4) One week after treatment, the symptoms such as fatigue, abdominal distension, anorexia have been improved in treatment group. 12 weeks later, the amounts of ascites were significantly reduced. No serious adverse reactions and complications occurred in 26 cases of transplant patients after treatment.
Conclusion:
(1) Mesenchymal stem cells from isolated umbilical cord are less damaged after cryopreservation and recovery. After several passages, cells had less differentiation, more stable proliferation.
(2) Human umbilical cord mesenchymal stem cells were detected by flow cytometry, the expression of mesenchymal stem cell phenotype, did not express hematopoietic stem cell phenotype. Cultured Cells and bone marrow mesenchymal stem cells were in the same of phenotypic expression.
(3) Treatment of hepatic cirrhosis by human umbilical cord mesenchymal stem cells can increase patient’s ALB, PA, Fbg, shorten the PT and improve clinical symptoms.
(4) Human umbilical cord mesenchymal stem cell transplantation in patients with hepatic cirrhosis is safe.
引文
[1] Bartholomew A,Sturgeon C,Siatskas M,et al.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol,2002,30:42-48.
[2] Fang B,Song Y,Lin Q,et al. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children.Pediatr Transplant,2007,11(7):814-817.
[3] Gojo S,Gojo N,Takeda Y,In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[4] Parekkadan B,VanPoll D,Megeed Z, et al.Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells[J]. Biochem Biophys Res Commun,2007,363 (2): 247-252.
[5]张颢,张浪辉,陈志哲,等.人脐带间充质干细胞体外分离、培养、扩增方法、生物学特征研究[J].江西医学院学报,2007,47(5):1-4.
[6]张彦,黄平平.人脐带间充质干细胞的生物特性及应用前景[J].国际移植与血液净化杂志,2007,5(4):39-42.
[7] Bianco P,Riminucci M,Gronthos S,et al. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells,2001,19:180-192.
[8]潘兴华,庞荣清,张布振.干细胞与肝脏功能重建的研究现状与展望[J].World Chin J Digestol,2005,13(7):823-830.
[9] Klyushnenkova E,Mosca JD,Zernetkina V. T cell responses to allogeneic human mesenchymal stem cell:immunogenicity,tolerance,and suppression[J].J Biomed Sci,2005,12(1):47-57.
[10] Gojo S,Gojo N,Takeda Y.In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[11]黎娇,朱争艳.脐带间充质干细胞的分离鉴定及肝病治疗的研究进展[J],国际生物医学工程杂志,2009,32(3):190-193.
[12]吕璐璐,宋水平,魏旭东,等.人脐带和骨髓源间充质干细胞生物学特征的对比研究[J].中国实验血液学杂志,2008,16(1):140-146.
[13] Lu LL,Liu YJ,Yang SG,et al.Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials[J].Haematologica,2006,91(8):1017-1062.
[1]潘兴华,庞荣清,张布振.干细胞与肝脏功能重建的研究现状与展望[J].World Chin J Digestol,2005,13(7):823-830.
[2] Sigal SH,Rajvanshi P,Gorla GR,et,al.Partial hepatectomy-induced polyploidy attenuates hepatocyte replication and activates cell aging events[J].Am J Physiol 1997,276:1260-1272.
[3] Xu CS,Zhao LF,Yang KJ,et al.The origination and action of the hepatic stems cells. Shiyan shengwu xuebao 2004,37:72-77.
[4] Malcolm RA.Liver regeneration with reference to stem cells.Cell Develo Bio 2002,13:385-387.
[5] Vessey CJ,De lA,Hall PM.Hepatic stem cells:a review Pathology,2001,33:130-141.
[6] Laurson J,Selden C,Hodgson HJ Hepatocyte progenitors in man and in rodents-multiple pathways,multiple candidates Int J Exp Pathol,2005,86:1-18.
[7] Gojo S,Gojo N,Takeda Y,In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[8] Yu J,Thomson JA. Pluripotent stem cell lines[J]. Genes Dev,2008,22 (15):1987-1997.
[9] Wan CD,Cheng R,Wang HB,et al. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model[J].Hepatobiliary Pancreat Dis Int,2008,7(1):29-33.
[10] Lange C, Bruns H, Kluth D,et al. Hepatocytic differentiation of mesenchymal stem cells in co-cultures with fetal liver cells [J].World J Gastroenterol,2006,12(15): 2387-2394.
[11] VanPoll D,Parekkadan B,Cho CH,et al. Mesenchymal stem cell derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo[J]. Hepatology,2008,47(5):1634-1643.
[12] Parekkadan B,VanPoll D,Megeed Z,et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells[J].Biochem Biophys Res Commun,2007,363 (2):247-252.
[1] Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cell.Science,1999,284:143-147.
[2] Mareschi K,Biasin E,Piacibello W,et al.Isolation of human mesenchymal stem cells:bone marrow versus umbilical cord blood.Haematologica,2001,86:1099-1100.
[3] Chamberlain G.Foxl A,Ashton B,et al. Concise review mesenchymal stem cell: their phenotype,differentiation capacity,immunological features, and potential for homing. Stem Cells,2007,25:2739-2749.
[4]张彦,黄平平.人脐带间充质干细胞的生物特性及应用前景[J].国际移植与血液净化杂志,2007,5(4):39-42.
[5]汪浩文,何志旭,王志华,等.大鼠骨髓间充质干细胞多向分化潜能的研究[J].复旦大学(医学版),2009,36(5):528-532.
[6]何绍清,罗振宇,刘秋英,等.人脐带间充质干细胞分离培养及向成骨细胞的分化[J].中国组织工程研究与临床康复,2010,14(14):2492-2496.
[7]李丽艳,杜江,黄金中.兔软骨细胞诱导人脐血间充质干细胞成软骨的可行性[J].中国组织工程研究与临床康复,2009,13(49):9713-9716.
[8]王斌,洪小杨,杜江,等.人脐带血间充质干细胞体外诱导分化为神经元样细胞的可行性[J].实用儿科临床杂志,2006,21(10):617-619.
[9]宋兆峰,季晓平,王晓荣,等.骨髓间充质干细胞体外定向诱导分化为心肌样细胞的实验研究[J].山东大学学报(医学版),2006,44(10):1021-1023.
[10]王爱红,何红燕,罗敏洁,等.人脐带间充质干细胞向胰岛样细胞的分化[J].中国组织工程研究与临床康复,2008,12(21):4102-4106.
[11]王陆飞,石艳,苏冠方,等.骨髓间充质干细胞在大鼠眼内分化情况的研究[J].中国实验诊断学,2009,13(8):1007-1009
[12] Yu J,Thomson JA. Pluripotent stem cell lines [J]. Genes Dev,2008,22 (15):1987-1997.
[13] Parekkadan B,VanPoll D,Megeed Z,et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells[J].Biochem Biophys Res Commun,2007,363 (2):247-252.
[14] Lange C,Bruns H,Kluth D,et al. Hepatocytic differentiation of mesenchymal stem cells in co-cultures with fetal liver cells[J].World J Gastroenterol,2006,12(15): 2387-2394.
[15] Wan CD,Cheng R,Wang HB,et al.Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model[J].Hepatobiliary Pancreat Dis Int,2008,7(1):29-33.
[16] VanPoll D,Parekkadan B,Cho CH,et al. Mesenchymal stem cell derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo[J]. Hepatology,2008,47(5):1634-1643.
[17]夏云飞,顾志峰.间充质干细胞与调节性T细胞的研究进展[J].Journal of University(Medical Sciences),2010:30(3).
[18] Lu L, Cantor H. Generation and regulation of CD8+ regulatory T cell[J]. Cell Mol Immunol,2008,5(6):401-406.
[19] Pyzik M.Piccirillo CA. TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+T cell subsets[J].J Leukoc Biol,2007,82(2):335-346.
[20] Kronenberg M,Rudensky A.Rudensky A. Regulation of immunity by self-reactive Tcells[J].Nature,2005,435(7042):598-604.
[21] Di LM,Del PB,De LM,et al. Mesenchymal stem cells recruit and regulate T regulatory cells[J].ExpHematol,2008,36(3):309-318.
[22] Cederbom L,Hall H,Lvars F.CD4+CD25+regulatory T cells downregulate co-stimulatory molecules on antigen-presenting cells[J].Eur J Immunol,2000,30(6):1538-1543.
[23] Corcione A,Benvenuto F,Ferretti E,et al.Human mesenchymal stem cslls modulate B-cell function[J].Blood,2006,107(1):367.
[24] Grazia MS, Heba A,Flavio B,et al.Mesenchymal stem cells inhibit natural killer cell proliferation,cytotoxicity and cytokine production:role of indoleamine 2,3-dioxy-genase and prostaglandin E2[J].Abstracts,2009,3:133.
[25] Aggarwal S,Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses[J].Blood,2005,105:1815.
[26] Nicola M,Carlo SC,Magni M,et al,Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J].Blood,2002,99(10):3838-3843.
[27] Beyth S,Borovsky Z,Mevoracb D,et al.Human mesenchymal stem cells alter antigen -presentingcell maturation and induce T-cell unresponsiveness[J], Blood, 2005,105(5):2214-2219.
[28]张颢,张浪辉,陈志哲,等.人脐带间充质干细胞体外分离、培养、扩增方法、生物学特征研究[J].江西医学院学报,2007,47(5):1-4.
[29] Djouda F,Plence P,Bony C,et al.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic amimals[J].Blood,2003,102(10):3837-3844.
[30] Gojo S,Gojo N,Takeda Y,In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[31]马晓菁,谢东珊,张娇,等.大鼠骨髓间充质干细胞在创面愈合中的作用[J].中国组织工程研究与临床康复,2009,13(32):6299-6302.
[32]邓启垣,陈灿,黄石安,等.间充质干细胞归巢的研究进展[J].医学综述,2010,16(5):678-681.
[33] Bhakta S,Hong P,Koc O.The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation[J].Cardiovase Revasc Med,2006,7(1):19-24.
[34] Wang Y,Deng YB,Zhou GQ.SDF-1/CXCR4 mediated Migration of Systemically Transplanted Bone Marrow Stromal Cslls Towards Ischemic Brain Lesion in A Rat Model[J].Brain Res,2008,1195(2):104-112.
[35] Ruster B,Gottig S,Ludig RJ,et al.Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells[J].Blood,2006,108(12):3938-3944.
[36] Segers VF,Van RI,Andries LJ,et al.Mesenchymal stem cell adhesion to cardiac microvascular endothelium:Activators and mechanisms[J].Am J Physiol Heart Circ Physiol,2006,290(4):H1370-H1377.
[37] Schmidt A,Ladage D,Steingen C,et al.Mesenchymal stem cells transmigrate over the endothelial barrier[J].Eur J Cell Biol,2006,85(11):1179-1188.
[38] Sigal SH,Rajvanshi P,Gorla GR,Sokhi RP,Saxena R,Gebhard DR,Reid LM,Gupta S.Partial hepatectomy-induced polyploidy attenuates hepatocyte replication and activates cell aging events.Am J Physiol,1997,276:1260-1272.
[39]王豪勋,马军,段芳龄,等.骨髓间充质干细胞治疗肝硬化的动物实验研究[J].胃肠病学和肝病学杂志,2006,15(4):365-368.
[40]张卫光,俞敏俊,田珑,等.人间充质干细胞移植改善四氯化碳诱导性肝硬化大鼠的肝纤维化[J].解剖学报,2006,37(2):158-162.
[41]吕璐璐,宋水平,魏旭东,等.人脐带和骨髓源间充质干细胞生物学特征的对比研究[J].中国实验血液学杂志,2008,16(1):140-146.
[42] Lu LL,Liu YJ,Yang SG,et al.Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials[J].Haematologica,2006,91(8):1017-1062.
[2] Fang B,Song Y,Lin Q,et al. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children.Pediatr Transplant,2007,11(7):814-817.
[3] Gojo S,Gojo N,Takeda Y,In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[4] Parekkadan B,VanPoll D,Megeed Z, et al.Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells[J]. Biochem Biophys Res Commun,2007,363 (2): 247-252.
[5]张颢,张浪辉,陈志哲,等.人脐带间充质干细胞体外分离、培养、扩增方法、生物学特征研究[J].江西医学院学报,2007,47(5):1-4.
[6]张彦,黄平平.人脐带间充质干细胞的生物特性及应用前景[J].国际移植与血液净化杂志,2007,5(4):39-42.
[7] Bianco P,Riminucci M,Gronthos S,et al. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells,2001,19:180-192.
[8]潘兴华,庞荣清,张布振.干细胞与肝脏功能重建的研究现状与展望[J].World Chin J Digestol,2005,13(7):823-830.
[9] Klyushnenkova E,Mosca JD,Zernetkina V. T cell responses to allogeneic human mesenchymal stem cell:immunogenicity,tolerance,and suppression[J].J Biomed Sci,2005,12(1):47-57.
[10] Gojo S,Gojo N,Takeda Y.In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[11]黎娇,朱争艳.脐带间充质干细胞的分离鉴定及肝病治疗的研究进展[J],国际生物医学工程杂志,2009,32(3):190-193.
[12]吕璐璐,宋水平,魏旭东,等.人脐带和骨髓源间充质干细胞生物学特征的对比研究[J].中国实验血液学杂志,2008,16(1):140-146.
[13] Lu LL,Liu YJ,Yang SG,et al.Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials[J].Haematologica,2006,91(8):1017-1062.
[1]潘兴华,庞荣清,张布振.干细胞与肝脏功能重建的研究现状与展望[J].World Chin J Digestol,2005,13(7):823-830.
[2] Sigal SH,Rajvanshi P,Gorla GR,et,al.Partial hepatectomy-induced polyploidy attenuates hepatocyte replication and activates cell aging events[J].Am J Physiol 1997,276:1260-1272.
[3] Xu CS,Zhao LF,Yang KJ,et al.The origination and action of the hepatic stems cells. Shiyan shengwu xuebao 2004,37:72-77.
[4] Malcolm RA.Liver regeneration with reference to stem cells.Cell Develo Bio 2002,13:385-387.
[5] Vessey CJ,De lA,Hall PM.Hepatic stem cells:a review Pathology,2001,33:130-141.
[6] Laurson J,Selden C,Hodgson HJ Hepatocyte progenitors in man and in rodents-multiple pathways,multiple candidates Int J Exp Pathol,2005,86:1-18.
[7] Gojo S,Gojo N,Takeda Y,In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[8] Yu J,Thomson JA. Pluripotent stem cell lines[J]. Genes Dev,2008,22 (15):1987-1997.
[9] Wan CD,Cheng R,Wang HB,et al. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model[J].Hepatobiliary Pancreat Dis Int,2008,7(1):29-33.
[10] Lange C, Bruns H, Kluth D,et al. Hepatocytic differentiation of mesenchymal stem cells in co-cultures with fetal liver cells [J].World J Gastroenterol,2006,12(15): 2387-2394.
[11] VanPoll D,Parekkadan B,Cho CH,et al. Mesenchymal stem cell derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo[J]. Hepatology,2008,47(5):1634-1643.
[12] Parekkadan B,VanPoll D,Megeed Z,et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells[J].Biochem Biophys Res Commun,2007,363 (2):247-252.
[1] Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cell.Science,1999,284:143-147.
[2] Mareschi K,Biasin E,Piacibello W,et al.Isolation of human mesenchymal stem cells:bone marrow versus umbilical cord blood.Haematologica,2001,86:1099-1100.
[3] Chamberlain G.Foxl A,Ashton B,et al. Concise review mesenchymal stem cell: their phenotype,differentiation capacity,immunological features, and potential for homing. Stem Cells,2007,25:2739-2749.
[4]张彦,黄平平.人脐带间充质干细胞的生物特性及应用前景[J].国际移植与血液净化杂志,2007,5(4):39-42.
[5]汪浩文,何志旭,王志华,等.大鼠骨髓间充质干细胞多向分化潜能的研究[J].复旦大学(医学版),2009,36(5):528-532.
[6]何绍清,罗振宇,刘秋英,等.人脐带间充质干细胞分离培养及向成骨细胞的分化[J].中国组织工程研究与临床康复,2010,14(14):2492-2496.
[7]李丽艳,杜江,黄金中.兔软骨细胞诱导人脐血间充质干细胞成软骨的可行性[J].中国组织工程研究与临床康复,2009,13(49):9713-9716.
[8]王斌,洪小杨,杜江,等.人脐带血间充质干细胞体外诱导分化为神经元样细胞的可行性[J].实用儿科临床杂志,2006,21(10):617-619.
[9]宋兆峰,季晓平,王晓荣,等.骨髓间充质干细胞体外定向诱导分化为心肌样细胞的实验研究[J].山东大学学报(医学版),2006,44(10):1021-1023.
[10]王爱红,何红燕,罗敏洁,等.人脐带间充质干细胞向胰岛样细胞的分化[J].中国组织工程研究与临床康复,2008,12(21):4102-4106.
[11]王陆飞,石艳,苏冠方,等.骨髓间充质干细胞在大鼠眼内分化情况的研究[J].中国实验诊断学,2009,13(8):1007-1009
[12] Yu J,Thomson JA. Pluripotent stem cell lines [J]. Genes Dev,2008,22 (15):1987-1997.
[13] Parekkadan B,VanPoll D,Megeed Z,et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells[J].Biochem Biophys Res Commun,2007,363 (2):247-252.
[14] Lange C,Bruns H,Kluth D,et al. Hepatocytic differentiation of mesenchymal stem cells in co-cultures with fetal liver cells[J].World J Gastroenterol,2006,12(15): 2387-2394.
[15] Wan CD,Cheng R,Wang HB,et al.Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model[J].Hepatobiliary Pancreat Dis Int,2008,7(1):29-33.
[16] VanPoll D,Parekkadan B,Cho CH,et al. Mesenchymal stem cell derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo[J]. Hepatology,2008,47(5):1634-1643.
[17]夏云飞,顾志峰.间充质干细胞与调节性T细胞的研究进展[J].Journal of University(Medical Sciences),2010:30(3).
[18] Lu L, Cantor H. Generation and regulation of CD8+ regulatory T cell[J]. Cell Mol Immunol,2008,5(6):401-406.
[19] Pyzik M.Piccirillo CA. TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+T cell subsets[J].J Leukoc Biol,2007,82(2):335-346.
[20] Kronenberg M,Rudensky A.Rudensky A. Regulation of immunity by self-reactive Tcells[J].Nature,2005,435(7042):598-604.
[21] Di LM,Del PB,De LM,et al. Mesenchymal stem cells recruit and regulate T regulatory cells[J].ExpHematol,2008,36(3):309-318.
[22] Cederbom L,Hall H,Lvars F.CD4+CD25+regulatory T cells downregulate co-stimulatory molecules on antigen-presenting cells[J].Eur J Immunol,2000,30(6):1538-1543.
[23] Corcione A,Benvenuto F,Ferretti E,et al.Human mesenchymal stem cslls modulate B-cell function[J].Blood,2006,107(1):367.
[24] Grazia MS, Heba A,Flavio B,et al.Mesenchymal stem cells inhibit natural killer cell proliferation,cytotoxicity and cytokine production:role of indoleamine 2,3-dioxy-genase and prostaglandin E2[J].Abstracts,2009,3:133.
[25] Aggarwal S,Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses[J].Blood,2005,105:1815.
[26] Nicola M,Carlo SC,Magni M,et al,Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J].Blood,2002,99(10):3838-3843.
[27] Beyth S,Borovsky Z,Mevoracb D,et al.Human mesenchymal stem cells alter antigen -presentingcell maturation and induce T-cell unresponsiveness[J], Blood, 2005,105(5):2214-2219.
[28]张颢,张浪辉,陈志哲,等.人脐带间充质干细胞体外分离、培养、扩增方法、生物学特征研究[J].江西医学院学报,2007,47(5):1-4.
[29] Djouda F,Plence P,Bony C,et al.Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic amimals[J].Blood,2003,102(10):3837-3844.
[30] Gojo S,Gojo N,Takeda Y,In vivo cardiovasculogenesis by directinjection of isolated adult mesenchymal stem cells[J].Exp Cell Res,2003,288(1):51-59.
[31]马晓菁,谢东珊,张娇,等.大鼠骨髓间充质干细胞在创面愈合中的作用[J].中国组织工程研究与临床康复,2009,13(32):6299-6302.
[32]邓启垣,陈灿,黄石安,等.间充质干细胞归巢的研究进展[J].医学综述,2010,16(5):678-681.
[33] Bhakta S,Hong P,Koc O.The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation[J].Cardiovase Revasc Med,2006,7(1):19-24.
[34] Wang Y,Deng YB,Zhou GQ.SDF-1/CXCR4 mediated Migration of Systemically Transplanted Bone Marrow Stromal Cslls Towards Ischemic Brain Lesion in A Rat Model[J].Brain Res,2008,1195(2):104-112.
[35] Ruster B,Gottig S,Ludig RJ,et al.Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells[J].Blood,2006,108(12):3938-3944.
[36] Segers VF,Van RI,Andries LJ,et al.Mesenchymal stem cell adhesion to cardiac microvascular endothelium:Activators and mechanisms[J].Am J Physiol Heart Circ Physiol,2006,290(4):H1370-H1377.
[37] Schmidt A,Ladage D,Steingen C,et al.Mesenchymal stem cells transmigrate over the endothelial barrier[J].Eur J Cell Biol,2006,85(11):1179-1188.
[38] Sigal SH,Rajvanshi P,Gorla GR,Sokhi RP,Saxena R,Gebhard DR,Reid LM,Gupta S.Partial hepatectomy-induced polyploidy attenuates hepatocyte replication and activates cell aging events.Am J Physiol,1997,276:1260-1272.
[39]王豪勋,马军,段芳龄,等.骨髓间充质干细胞治疗肝硬化的动物实验研究[J].胃肠病学和肝病学杂志,2006,15(4):365-368.
[40]张卫光,俞敏俊,田珑,等.人间充质干细胞移植改善四氯化碳诱导性肝硬化大鼠的肝纤维化[J].解剖学报,2006,37(2):158-162.
[41]吕璐璐,宋水平,魏旭东,等.人脐带和骨髓源间充质干细胞生物学特征的对比研究[J].中国实验血液学杂志,2008,16(1):140-146.
[42] Lu LL,Liu YJ,Yang SG,et al.Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials[J].Haematologica,2006,91(8):1017-1062.